fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Alexion to Present Key Data on Ultomiris and Soliris for gMG at AANEM and MGFA 2024

Written by | 17 Oct 2024

Alexion, AstraZeneca Rare Disease, will present data from its leading generalised myasthenia gravis (gMG) portfolio at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and… read more.

Complete Response for regulatory review of Ultomiris in the treatment of adult patients with neuromyelitis optica spectrum disorder – AstraZeneca

Written by | 15 Sep 2023

The FDA has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for long-acting C5 complement inhibitor Ultomiris (ravulizumab-cwvz) for the treatment of adult… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.